Brokerages expect that Emergent Biosolutions Inc (NYSE:EBS) will post $188.20 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Emergent Biosolutions’ earnings, with the lowest sales estimate coming in at $185.00 million and the highest estimate coming in at $191.40 million. Emergent Biosolutions posted sales of $149.43 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 25.9%. The firm is expected to issue its next earnings results on Thursday, November 1st.

On average, analysts expect that Emergent Biosolutions will report full-year sales of $746.54 million for the current year, with estimates ranging from $743.50 million to $751.90 million. For the next fiscal year, analysts anticipate that the company will post sales of $826.06 million per share, with estimates ranging from $756.30 million to $931.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.19. The company had revenue of $220.20 million for the quarter, compared to analysts’ expectations of $208.94 million. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. Emergent Biosolutions’s quarterly revenue was up 118.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.13 EPS.

EBS has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Tuesday, May 1st. Chardan Capital upped their target price on shares of Emergent Biosolutions from $53.00 to $57.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Wells Fargo & Co reaffirmed a “market perform” rating on shares of Emergent Biosolutions in a report on Wednesday, April 25th. Cantor Fitzgerald initiated coverage on shares of Emergent Biosolutions in a report on Monday, June 11th. They issued a “buy” rating and a $62.00 target price on the stock. Finally, Argus initiated coverage on shares of Emergent Biosolutions in a report on Wednesday, June 13th. They issued a “buy” rating and a $62.00 target price on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $59.57.

Shares of EBS stock traded up $0.28 on Tuesday, reaching $59.31. The stock had a trading volume of 4,558 shares, compared to its average volume of 332,335. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.15 and a current ratio of 5.59. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 30.93, a PEG ratio of 1.18 and a beta of 1.20. Emergent Biosolutions has a 12 month low of $34.56 and a 12 month high of $60.00.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 36,318 shares of the stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $55.98, for a total value of $2,033,081.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Abdun-Nabi sold 15,785 shares of the stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $52.11, for a total transaction of $822,556.35. Following the completion of the transaction, the chief executive officer now directly owns 197,343 shares in the company, valued at $10,283,543.73. The disclosure for this sale can be found here. Over the last three months, insiders sold 88,856 shares of company stock worth $4,832,028. Insiders own 13.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Stratos Wealth Partners LTD. bought a new position in shares of Emergent Biosolutions during the first quarter worth approximately $134,000. PNC Financial Services Group Inc. increased its holdings in shares of Emergent Biosolutions by 108.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 1,482 shares during the period. SG Americas Securities LLC bought a new position in shares of Emergent Biosolutions during the first quarter worth approximately $171,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Emergent Biosolutions during the 1st quarter worth approximately $190,000. Finally, Sei Investments Co. boosted its position in shares of Emergent Biosolutions by 5,992.1% during the 1st quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 3,775 shares in the last quarter. 82.72% of the stock is currently owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Further Reading: What does earnings per share mean?

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.